How business is dealing with the AIDS epidemic.
Employers geared up for astronomical HIV-related claims, but the avalanche never came. As new treatments improve prognoses and increase costs, the innovations of forward-thinking companies suggest useful strategies.
Gerson
V
V
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000191:economics* / Q000453:epidemiology; D000328:Adult; D019380:Anti-HIV Agents / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics* / Q000453:epidemiology; D006264:Health Benefit Plans, Employee / Q000191:economics*; D006265:Health Care Coalitions / Q000191:economics / Q000458:organization & administration; D006801:Humans; D007343:Insurance Carriers; D007750:Labor Unions; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration